Visipaque
PreclinicalSmall molecule
Visipaque is one of 45 small molecule programs targeting Nephropathy. It is currently in Preclinical.
2
Indications
5
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Approved
Rituxan
RocheApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Theo-Dur
PfizerApproved
Crestor
AstraZenecaApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Micardis
Boehringer IngelheimApproved
Livalo
MMedicure
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Zocor
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Single Dose1 trial
Intravenous1 trial
Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN
Unknown status·—·N/A·NCT02718521·400 enrolled
Chronic Kidney Disease1 trial
Pediatric1 trial
Nephropathy1 trial
Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy
Completed·—·N/A·NCT02405377·264 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Visipaque. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- GGE Healthcare